363 related articles for article (PubMed ID: 21631494)
21. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
22. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
23. Long-term efficacy and tolerability of rizatriptan wafers in migraine.
Cady R; Crawford G; Ahrens S; Hairwassers D; Getson A; Visser WH; Lines C;
MedGenMed; 2001 Jun; 3(3):1. PubMed ID: 11549974
[TBL] [Abstract][Full Text] [Related]
24. Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
Maghbooli M; Golipour F; Moghimi Esfandabadi A; Yousefi M
Phytother Res; 2014 Mar; 28(3):412-5. PubMed ID: 23657930
[TBL] [Abstract][Full Text] [Related]
25. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
27. Sumatriptan (oral route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008615. PubMed ID: 22336849
[TBL] [Abstract][Full Text] [Related]
28. A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study.
Guilbot A; Bangratz M; Ait Abdellah S; Lucas C
BMC Complement Altern Med; 2017 Aug; 17(1):433. PubMed ID: 28854909
[TBL] [Abstract][Full Text] [Related]
29. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial.
Dowson AJ; Charlesworth BR; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(11):839-51. PubMed ID: 12921494
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group.
Bousser MG; D'Allens H; Richard A
J Intern Med; 1993 Aug; 234(2):211-6. PubMed ID: 8393474
[TBL] [Abstract][Full Text] [Related]
32. Zolmitriptan for acute migraine attacks in adults.
Bird S; Derry S; Moore RA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD008616. PubMed ID: 24848613
[TBL] [Abstract][Full Text] [Related]
33. Feverfew for preventing migraine.
Pittler MH; Ernst E
Cochrane Database Syst Rev; 2004; (1):CD002286. PubMed ID: 14973986
[TBL] [Abstract][Full Text] [Related]
34. Double-blind, placebo-controlled, crossover study of early-intervention with sumatriptan 85/naproxen sodium 500 in (truly) episodic migraine: what's neck pain got to do with it?
Calhoun AH; Ford S
Postgrad Med; 2014 Mar; 126(2):86-90. PubMed ID: 24685971
[TBL] [Abstract][Full Text] [Related]
35. [Studies on the antimigraine action of Feverfew (Tanacetum parthenium (L.) Sch. Bip.)].
Studzińska-Sroka E; Znajdek-Awizeń P; Gawron-Gzella A
Wiad Lek; 2013; 66(2 Pt 2):195-9. PubMed ID: 25775817
[TBL] [Abstract][Full Text] [Related]
36. Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study.
Tfelt-Hansen P; Bach FW; Daugaard D; Tsiropoulos I; Riddersholm B
J Headache Pain; 2006 Dec; 7(6):389-94. PubMed ID: 17164991
[TBL] [Abstract][Full Text] [Related]
37. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA.
Dodick DW; Goadsby PJ; Schwedt TJ; Lipton RB; Liu C; Lu K; Yu SY; Severt L; Finnegan M; Trugman JM
Lancet; 2023 Dec; 402(10419):2307-2316. PubMed ID: 37979595
[TBL] [Abstract][Full Text] [Related]
38. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine.
Cady RK; Saper J; Dexter K; Cady RJ; Manley HR
Headache; 2015 Apr; 55(4):529-42. PubMed ID: 25828648
[TBL] [Abstract][Full Text] [Related]
40. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study.
Krymchantowski AV; Barbosa JS
Cephalalgia; 2002 May; 22(4):309-12. PubMed ID: 12100094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
